Nasus Pharma (NSRX) CEO adds 15,000 shares at $2.04 in buy

Rhea-AI Filing Summary

Nasus Pharma Ltd Chief Executive Officer Dan Benjamin Teleman reported an open-market purchase of 15,000 Ordinary Shares of the company at $2.04 per share. Following this transaction, he directly holds 21,246 Ordinary Shares, indicating a higher personal equity stake in the business.

Insider Trade Summary

Net Buyer: 15,000 shares ($30,600)

Net Buy 1 txn

Insider Teleman Dan Benjamin

Role Chief Executive Officer

Bought 15,000 shs ($31K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	15,000	$2.04	$31K

Holdings After Transaction: Ordinary Shares — 21,246 shares (Direct)

Footnotes (1)

Key Figures

Shares purchased: 15,000 shares Purchase price: $2.04 per share Shares held after: 21,246 shares +1 more

4 metrics

Shares purchased 15,000 shares Open-market purchase of Ordinary Shares

Purchase price $2.04 per share Price paid in the reported transaction

Shares held after 21,246 shares Direct ownership after the transaction

Net buy shares 15,000 shares Net change in position from this Form 4

Key Terms

open-market purchase, Ordinary Shares, Form 4, Chief Executive Officer

4 terms

open-market purchase financial

"described as an open-market purchase of 15,000 Ordinary Shares"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Ordinary Shares financial

"reported an open-market purchase of 15,000 Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 regulatory

"according to a Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Executive Officer financial

"Chief Executive Officer Dan Benjamin Teleman reported an open-market purchase"

A chief executive officer (CEO) is the top leader of a company, responsible for making major decisions, setting goals, and guiding the organization’s overall direction. Think of the CEO as the captain of a ship, steering it toward success. Investors pay close attention to the CEO because their leadership and strategy can significantly influence the company's performance and future growth.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teleman Dan Benjamin

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/31/2026		P		15,000	A	$2.04	21,246	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Dan Benjamin Teleman	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Nasus Pharma (NSRX) CEO buy in this Form 4 filing?

The CEO of Nasus Pharma, Dan Benjamin Teleman, bought 15,000 Ordinary Shares in an open-market transaction. This was reported as a direct ownership purchase and reflects an increase in his personal equity position in the company.

At what price did the Nasus Pharma (NSRX) CEO purchase shares?

Dan Benjamin Teleman purchased 15,000 Ordinary Shares at $2.04 per share. This price reflects the cost per share in the reported open-market transaction disclosed in the Form 4 insider trading report.

How many Nasus Pharma (NSRX) shares does the CEO hold after the transaction?

After the reported purchase, Dan Benjamin Teleman holds 21,246 Ordinary Shares of Nasus Pharma. This total represents his direct ownership position following the acquisition of 15,000 additional shares in the open market.

Is the Nasus Pharma (NSRX) CEO’s transaction a buy or a sell?

The transaction is a buy. The Form 4 lists a transaction code “P” and describes it as an open-market purchase, with 15,000 Ordinary Shares acquired by Dan Benjamin Teleman, increasing his directly held stake in Nasus Pharma.

What type of security did the Nasus Pharma (NSRX) Form 4 disclose?

The Form 4 discloses a transaction in Nasus Pharma’s Ordinary Shares. These are non-derivative equity securities, meaning the CEO bought the shares themselves directly rather than exercising options or other derivative instruments.